Survival of patients with advanced non-small-cell lung cancer at Ubon Ratchathani Cancer Center, Thailand

Southeast Asian Journal of Tropical Medicine and Public Health

Volumn 36, Issue 4, 2005, Pages 994-1006

  Srisam ang, Kitiporn ^a   Podhipak, Amornrath ^b   Narksawat, Kulaya ^b   Supaattagorn, Pongsatorn ^a   Tipayamongkholgul, Mathuros ^b  

^a Ubonratchathani Cancer Center   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 27744528397     PISSN: 01251562     EISSN: 26975718     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Ahn YC, Park K, Kim DY, et al. Preoperative concurrent chemoradiotherapy for stage IIIA non-small cell lung cancer. Acta Oncol 2001; 40: 588-92.
2. Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/ etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of southwest oncology group phase II study 8805. J Clin Oncol 1995; 13: 1880-92.
3. Bouchardy C, Fioretta G, De Perrot M, Obradovic M, Spiliopoulos A. Determinants of long term survival after surgery for cancer of the lung. Cancer 1999; 86: 2229-37.
4. Brownson RC, Alavanja MCR, Caporaso N, Simoes EJ, Chang JC. Epidemiology and prevention of lung cancer in nonsmokers. Epidemiol Rev 1998; 20: 218-36.
5. Cellerino R, Tummarello D Guidi F. A randomised trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer. J Clin Oncol 1991; 9: 1453-61.
6. Choi NC, Carey RW, Daley W, et al. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. J Clin Oncol 1997; 15: 712-22.
7. Cullen MH, Billingham LJ, Woodroffe CM, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999; 17: 3188-94.
8. Dev D, Capewell S, Sankaran R, Lumb D, Sudlow MF. Adenocarcinoma of the lung - clinical features and survival. Resp Med 1996; 90: 333-7.
9. Dillman RO, Herndon J, Seagren SL, Eaton Jr WL, Green MR. Improved survival in stage HI non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996; 88: 1210-5.
10. Douple EB, Richmond RC. Enhancement of the potentiation of radiotherapy by platinum drugs in a mouse tumor. Int J Radiat Oncol Biol Phys 1982; 8: 501-3.
11. Eagan RT, Ruud C, Lee RE, Pairoiero PC, Gail MH. Pilot study of induction therapy with cyclophosphamide, doxorubicin, and cisplatin (CAP) and chest irradiation prior to thoracotomy in initially inoperable stage III MO non-small-cell lung cancer. Cancer Treat Rep 1987; 71: 895-900.
12. Edelman MJ, Gandara DR, Ill MR, Benfield JR. Multimodality therapy in stage III non-small-cell lung cancer. Ann Thorac Surg 1996; 61: 1564-72.
13. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985; 312: 1604-8.
14. th ed. Philadelphia, USA: WB Saunders, 2001: 598-628.
15. Green LS, Fortoul TI, Ponciano G, Robles C, Rivero O. Bronchogenic cancer in patients under 40 years old: The experience of a Latin American country. Chest 1993; 104: 1477-81.
16. Herbst RS, Hidalgo M, Pierson AS, Holden SN, Bergen M, Eckhardt SG. Angiogenesis inhibitors in clinical development for lung cancer. Semi Oncol 2002; 29 (suppl 4): 66-77.
17. Hickish TF, Smith IE, O'Brien MER, Ashley S, Middleton G. Clinical benefit from palliative chemotherapy in non-small-cell lung cancer extends to the elderly and those with poor prognostic factors. Br J Cancer 1998; 28-33.
18. Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19: 3210-8.
19. Martin J, Ginsberg RJ, Venkatraman ES, et al. Long-term results of combined-modality therapy in resectable non-small-cell lung cancer. J Clin Oncol 2002; 20: 1989-95.
20. Milstein D, Kuten A, Saute M, et al. preoperative concurrent chemoradiotherapy for unresectable stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 1996; 34: 1125-32.
21. Paesmans M, Sculier JP, Libert P, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. J Clin Oncol 1995; 13: 1221-30.
22. Phunmanee A, Sukprasert A, Sriamporn S, Kamsa-ard S. Analysis of staging, treatment, and survival among lung cancer patients: a hospital based study. Thai J Tuberc Chest Dis 2001; 22: 243-53.
23. Rapp E, Pater JL, Willan A. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer - report of a Canadian multicenter randomized trial. J Clin Oncol 1988; 6: 633-41.
24. Ratanatharathorn V, Sirachainan E, Jirajarus M. Effects of paclitaxel and carboplatin on quality of life and survival in patients with advanced non-small-cell lung cancer. J Med Assoc Thai 2000; 83: 1059-67.
25. Riantawan P, Tungsagunwattana S, Subhannachart P, Yodtasurodom C. Histologic types, staging, resectability, and smoking among Thai patients with lung cancer. J Med Assoc Thai 1999a; 82: 121-5.
26. Riantawan P, Titayanpong A, Chaisuksuwan R. Survival in patients with advance non-small-cell lung cancer receiving supportive care. J Med Assoc Thai 1999b; 82: 336-40.
27. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994; 86: 673-80.
28. Saunders M, Dische S, Barrett A, Harvey A, Griffiths G, Palmar M. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: mature data from the randomized multicenter trial. CHART steering committee. Radiother Oncol 1999; 52: 137-48.
29. Schaake-Koning C, Van Den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992; 326: 524-30.
30. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-8.
31. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095-103.
32. Socinski MA, Rosenman JG, Halle J, et al. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/ paclitatexcl in unresectable stage IIIA/B non-small-cell lung carcinoma. Cancer 2001; 92: 1213-23.
33. Srivatanakul P. Epidmiology of lung cancer in Thailand. Management of lung Cancer 1999. Chiangmai, Thailand: organized by Thai Society of Clinical Oncology and International Assocition for the study of lung cancer 24-26 Feb 1999: 8-13.
34. Vansteenkiste JF, De Leyn PR, Deneffe GJ, et al. Survival and prognostic factors in resected N2 non-small-cell lung cancer: a study of 140 cases. Ann Thorac Surg 1997; 63: 1441-50.
35. Wright CD, Menard MT, Wain JC, et al. Induction chemoradiation compared with induction radiation for lung cancer involving the superior sulcus. Ann Thorac Surg 2002; 73: 1541-4.